focu
upgrad rate gilead outperform
market perform increas price target follow
expand collabor drug discoveri
galapago glpg improv prospect sustain
opportun inflamm fibrosi beyond alreadi partner
nda-readi filgotinib believ phase develop
ipf phase
develop inhibitor osteoarthr oa
could support drug reacceler earn
growth drug support strong biolog rational
compel earli data includ fvc improv ipf
biomark reduct oa importantli addit
drug develop preclin potenti new
drug candid per year believ access
previous lack discoveri engin pipelin support
re-rat stock multipl expans overal
impress speed decis galapago deal
new leadership see option valu deal
gilead scienc galapago nv glpg today
announc global research develop collabor
agreement receiv exclus product licens
option right develop commerci current futur
molecul clinic develop preclin
program countri outsid europ addit
glpg agre amend certain term filgotinib
agreement increas glpg role commerci drug
europ
term agreement glpg receiv
up-front payment equiti invest expand
acceler research develop program glpg
fund lead discoveri develop autonom
end phase point option
acquir expand licens compound option
exercis glpg co-develop compound share
cost equal per agreement maintain option right
glpg pipelin throughout term addit
three year thereaft program enter clinic
develop prior end term
continu page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
non-gaap ep exclud stock-bas compens reflect adjust
compani data secur llc estim reuter
part agreement gain right glpg first-in-class autotaxin inhibitor
current phase develop idiopath pulmonari fibrosi ipf approv
us glpg receiv addit mileston payment addit
receiv option right glpg inhibitor current phase develop
osteoarthr oa follow complet phase option licens
us fee certain secondari endpoint met would pay
addit follow opt-in glpg elig receiv
regulatori commerci mileston program includ within collabor
make opt-in payment per program subsequ mileston commerci
glpg elig receiv tier royalti rang net sale glpg product
licens
addit focu filgotinib rheumatoid arthriti ra phase joint develop
glpg two compani amend term collabor increas glpg
involv filgotinib commerci eu agre split futur develop cost
equal vs cost split origin agreement glpg plan co-commerci
filgotinib profit share franc germani itali spain uk glpg retain
exclus right commerci belgium netherland luxembourg term
origin licens agreement remain effect includ total remain potenti mileston
potenti tier royalti payabl region outsid belgium franc germani itali
luxembourg netherland spain uk
regard equiti invest intend purchas new glpg share per
share repres premium glpg volume-weight averag price increas
gild stake glpg approxim previous glpg intend seek sharehold
approv allow increas ownership glpg issu
outstand share part agreement includ standstil restrict
seek acquir glpg increas stake glpg beyond intend
nomin two individu glpg board director follow complet transact expect
late
price target
arriv price target appli multipl ep estim risk includ
continu slow hcv patient volum emerg credibl competit threat merck
particular failur key pipelin program hbv nash failur secur meaning revenu
opportun
expect earn growth reacceler beyond continu hiv product growth
increment contribut galapagos-partnership program fibrosi inflamm
larg cap global commercial-stag biotechnolog compani discov develop small
molecul biolog drug global leadership hiv hcv expand beyond infecti
diseas liver diseas oncolog inflammation/fibrot diseas
